Xenetic Biosciences Inc Announces Research And Development Collaboration With The Scripps Research Institute To Advance Dnase Platform

Xenetic Biosciences, Inc., A Biopharmaceutical Company Focused On Advancing Innovative Immune-Oncology Technologies Addressing Hard To Treat Cancers, Today Announced It Has Entered Into A Research Funding And Option Agreement (The "Agreement") With The Scripps Research Institute ("Tsri") To Advance The Development Of The Company'S Systemic Dnase Program As Well As Its Dnase-Armored Car T Program. The Systemic Dnase Program Is Expected To Be Evaluated In Combination With Existing Therapies For The Potential Treatment Of Pancreatic Carcinoma And Other Solid Tumor Indications.Xenetic'S Dnase-Based Oncology Platform Is Designed To Target Neutrophil Extracellular Traps ("Nets"), Which Are Weblike Structures Composed Of Extracellular Chromatin Coated With Histones And Other Proteins. Nets Are Expelled By Activated Neutrophils, In Response To Microbial Or Pro-Inflammatory Challenges. However, Excessive Production Or Reduced Clearance Of Nets Can Lead To Aggravated Inflammatory And Autoimmune Pathologies, As Well As Creation And Support Of Pro-Tumorigenic Niches In The Case Of Cancer Growth And Metastasis, Thereby Potentially Limiting Response To Therapy."Scripps Has Been A Long-Standing Valued Collaboration Partner Of Ours And We Are Pleased To Further Extend Our Relationship Through This Agreement For Our Dnase-Based Oncology Platform. We Believe That The Team At Scripps Is Well-Equipped To Provide Valuable Insight And Generate Meaningful Data In Our Preclinical Development Program As We Work To Advance Toward The Clinic. We Look Forward To Exploring A Platform Technology That Has The Potential To Generate Much Needed Therapies For Pancreatic Carcinoma And Other Locally Advanced Or Metastatic Solid Tumors," Commented Jeffrey Eisenberg, Chief Executive Officer Of Xenetic.Under The Terms Of The Scripps Research Agreement, In Addition To Advancing Xenetic'S Existing Intellectual Property, Xenetic Has An Option To Acquire An Exclusive License To Any New Intellectual Property Arising From The Dnase Research Program. Xenetic Is Working Toward Its Planned First-In-Human Study To Evaluate Dnase Combined With Immune Checkpoint Inhibitors Or Chemotherapy.About Scripps ResearchScripps Research Is An Independent, Nonprofit Biomedical Institute Ranked The Most Influential In The World For Its Impact On Innovation. With Campuses In La Jolla, California, And Jupiter, Florida, It Is Advancing Human Health Through Profound Discoveries That Address Pressing Medical Concerns Around The Globe.Its Drug Discovery And Development Division, Calibr, Works Hand-In-Hand With Scientists Across Disciplines To Bring New Medicines To Patients As Quickly And Efficiently As Possible, While Teams At Scripps Research Translational Institute Harness Genomics, Digital Medicine And Cutting-Edge Informatics To Understand Individual Health And Render More Effective Healthcare.Scripps Research Also Trains The Next Generation Of Leading Scientists At Its Skaggs Graduate School, Consistently Named Among The Top 10 U.S. Programs For Chemistry And Biological Sciences. Learn More At Http://Www.Scripps.Edu.About Xenetic BiosciencesXenetic Biosciences, Inc. Is A Biopharmaceutical Company Focused On Advancing Innovative Immune-Oncology Technologies Addressing Hard To Treat Cancers. The Company'S Dnase Platform Is Designed To Improve Outcomes Of Existing Treatments, Including Immunotherapies, By Targeting Neutrophil Extracellular Traps (Nets), Which Have Been Implicated In Cancer Progression And Resistance To Cancer Treatments. Xenetic Is Currently Focused On Advancing Its Systemic Dnase Program Into The Clinic As An Adjunctive Therapy For Pancreatic Carcinoma And Locally Advanced Or Metastatic Solid Tumors.The Company Is Also Developing Its Personalized Car T Platform Technology, Xcart

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!